While several antiobesity drugs are available [23], treatment with glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for obesity management appears to be effective for and well tolerated by people with schizophrenia [24]. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.